

1 **NXT2 is the key player for nuclear RNA export in the human testis and critical for**
2 **spermatogenesis**

3
4 Ann-Kristin Dicke¹, Ammar Ahmedani², Lin Ma², Godfried W. van der Heijden³, Sophie A. Koser¹,
5 Claudia Krallmann⁴, Oguzhan Kalyon⁵, Miguel J. Xavier⁵, Joris A. Veltman⁵, Sabine Kliesch⁴, Nina
6 Neuhaus⁴, Noora Kotaja², Frank Tüttelmann^{1#}, Birgit Stallmeyer^{1#}

7
8 ¹Centre of Medical Genetics, Institute of Reproductive Genetics, University of Münster, Münster,
9 Germany

10 ²Institute of Biomedicine, Integrative Physiology and Pharmacology Unit, University of Turku,
11 Turku, Finland

12 ³Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Radboudumc,
13 Nijmegen, Netherlands.

14 ⁴Centre of Reproductive Medicine and Andrology, Department of Clinical and Surgical Andrology,
15 University Hospital Münster, Münster, Germany

16 ⁵Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne,
17 UK

18
19 #These authors contributed equally.

20
21 Correspondence: Birgit Stallmeyer, Centre for Medical Genetics, Institute of Reproductive
22 Genetics, University of Münster, Vesaliusweg 12-14, 48149 Münster, Germany,
23 birgit.stallmeyer@ukmuenster.de

24
25 **Keywords:** nuclear RNA export, nuclear transport, male infertility, non-obstructive azoospermia,
26 X chromosome, NXT2, NXF2, NXF3

27
28 **Word count:** 4,161 (excluding abstract, methods, references, figure legends); abstract: 148

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 **Abstract**

30 In eukaryotes, the nucleocytoplasmic export of bulk poly(A)⁺-mRNAs through the nuclear pore
31 complex is mediated by the ubiquitously expressed NXT1-NXF1 heterodimer. In humans, *NXT1*
32 has an X-chromosomal paralog, *NXT2*, which exhibits testis-enriched expression, suggesting a
33 role in spermatogenesis. Here, we report the *in vivo* interaction of *NXT2* with crucial components
34 of the nuclear export machinery, including NXF1, the testis-specific NXF1 paralogs NXF2 and
35 NXF3, and the nuclear pore complex proteins NUP93 and NUP214. Further, *NXT2*'s NTF2-like
36 domain mediates binding to NXF2 and NXF3. By identifying infertile men with loss-of-function
37 variants in *NXT2* and *NXF3*, we link the impaired *NXT2*-NXF activity to disturbed germ cell
38 development. The predominant absence of germ cells in men with *NXT2* deficiency indicates its
39 critical function already during fetal or first steps of germ cell development. In contrast, loss of
40 NXF3 affects later stages of spermatogenesis resulting in quantitatively and qualitatively impaired
41 sperm production.

42 **Introduction**

43 In eukaryotic cells, the nuclear envelope is an essential barrier with multiple functions. It separates
44 the nucleus, where precursor messenger RNA (pre-mRNA) is transcribed and processed into
45 mature mRNA, from the cytoplasm, where the mRNA is translated into protein. This separation
46 allows quality control by eliminating non-functional RNAs in the nucleus before they enter the
47 translation machinery and is, thus, involved in the regulation of gene expression¹. In addition, the
48 nuclear envelope prevents macromolecules from translocating freely between the two
49 compartments and has an important structural role in sheltering the genome². To regulate the
50 nucleocytoplasmic trafficking of macromolecules, such as proteins and RNA, massive
51 (~120 MDa) nuclear pore complexes (NPCs), consisting of multiple copies of about 30 different
52 nuclear pore proteins (nucleoporins/NUPs), are embedded in the nuclear envelope, forming
53 specialized channels³. Transcripts that passed nuclear quality control are bound to
54 ribonucleoproteins (RNPs), forming compact globules that are recognized and coated by
55 transcription export (TREX) complexes, which license the handoff to the nuclear export factor
56 heterodimer, composed of NXT1 (also known as p15/p15-1) and NXF1 (also known as TAP)^{4,5}.

57 NXF1 is a modular protein consisting of four highly conserved domains: a nuclear localization
58 signal, a non-canonical RNA-recognition motif domain (RRMD) essential for binding the cargo
59 mRNA, a nuclear transport factor 2 (NTF2)-like domain that mediates binding to NXT1, and a C-
60 terminal nuclear pore complex binding domain establishing the interaction with NUPs⁶⁻⁸. NXT1
61 consists almost exclusively of the NTF2-like domain and functions as a critical cofactor enhancing
62 nuclear pore complex binding of NXF1⁸.

63 NXF1 is highly evolutionarily conserved and its essential role in the nuclear export of
64 polyadenylated mRNAs is well established from yeast to mammals⁹. In humans, NXT1 and NXF1
65 are ubiquitously expressed and the NXT1-NXF1 export pathway is involved in bulk mRNA export
66 in diverse tissues¹⁰. Interestingly, humans have X-chromosomal paralogs of *NXT1* and *NXF1*,
67 known as *NXT2* and *NXF2*, *NXF3*, *NXF4*, and *NXF5*, which have a tissue-enriched/specific

68 expression profile. *NXT2* is specific to eutherians and shares ~75 % amino acid sequence
69 similarity with *NXT1*⁷. It binds to *NXF* proteins *in vitro*⁷, but the cellular function remains unclear.

70 Interestingly, in eutherians, *NXT2* has been demonstrated to have different expression profiles in
71 different lineages. While mouse *Nxt2* is ubiquitously expressed, human *NXT2* shows testis-
72 enriched expression, suggesting an evolutionarily young and specific role of the human *NXT2* in
73 spermatogenesis. Indeed, *Nxt2* has evolved conservatively in mice, implying functional
74 constraints as predominant force¹¹. In contrast, adaptive selection, which describes the
75 propagation of advantageous genetic variations through positive selection, has frequently
76 contributed to genetic changes in primate *NXT2*¹¹. This quite different evolutionary development
77 of the two *NXT2* orthologs indicates that the primate protein has acquired novel substrate- and/or
78 tissue-specific functions that not only differ from the function of *NXT1* but also from the function
79 of the murine *NXT2*¹¹.

80 Here, we demonstrate that not only *NXF1* but also its testis-specific paralogs *NXF2* and *NXF3*
81 belong to the human testicular interactome of *NXT2* and propose an adapted nuclear RNA export
82 pathway in the human testis with *NXT2* as the key player. In addition, we provide evidence that
83 an impaired testis-specific *NXT2* interactome leads to male infertility. Men with loss-of-function
84 (LoF) variants in *NXT2* show absence of sperm in the ejaculate (azoospermia) and near absence
85 of germ cells in their testes (non-obstructive azoospermia, NOA). In contrast, a man with a LoF
86 in *NXF3* produced very few, and predominantly immotile sperm. Taken together, this indicates
87 that the *NXT2* interactome likely plays critical roles during embryonic/fetal germ cell development
88 as well as during spermatogenesis in the adult testis.

89 **Results**

90 *A nuclear export pathway involving NXT2 in the adult human testis*

91 As *NXT2* shows a testis-enriched expression in humans and has been influenced by adaptive
92 selection in primates¹¹, it is likely that the encoded protein has evolved to acquire functions and
93 binding partners distinct from its paralog *NXT1*. Therefore, we aimed to identify the interactome
94 of *NXT2* *in vivo* by pulling down *NXT2* from adult human testis tissue lysates using a validated
95 antibody (Supplementary Figure 1a/b, Supplementary Table 1), followed by a mass spectrometry
96 analysis. Eight proteins, including *NXT2*, were significantly enriched compared to the IgG
97 pulldown control (Figure 1a, Supplementary Table 2). STRING interaction analysis of the pulled-
98 down proteins highlighted three major clusters (Figure 1b). The core cluster includes *NXT2* and
99 three members of the nuclear export factor protein family, *NXF1*, *NXF2*, and *NXF3*. A possible
100 function of *NXT2* in RNA export through the nuclear pore was strengthened by the identification
101 of two nucleoporins, *NUP93* and *NUP214*, in its interactome. In addition, the mass spectrometry
102 data indicated an interaction of *NXT2* with two ribosome biogenesis factors, *SPATA5* and
103 *SPATA5L1*. Gene Ontology analysis further supported a role for *NXT2* and its interaction partners
104 in nucleocytoplasmic RNA transport as evidenced by the enrichment in terms mRNA transport,
105 nuclear export and nuclear transport (Figure 1c). The main cellular component associated with
106 the *NXT2* interactome was the nuclear export factor complex (Figure 1d).

107 Interestingly, *NXF1* was also identified in the *NXT2* interactome. In a complex with *NXT1*, *NXF1*
108 is well-known to be involved in the ubiquitous nuclear export of bulk mRNA via translocation
109 through the nuclear pore complex¹² (Figure 1e). However, *NXT1* was absent from the *NXT2*-*NXF*
110 interactome, indicating that it cannot compensate for the testicular function of *NXT2* and, *vice*
111 *versa*, that *NXT2* is the main interaction partner of *NXF1* in the human testis.

112 The protein structures of *NXF2* and *NXF3* are very similar to that of *NXF1* (Supplementary
113 Figure 2). However, in contrast to *NXF1*, *NXF2* and 3 are encoded by X-chromosomal genes and
114 are specifically expressed in the testis (Figure 1f), arguing for a testis-specific RNA export
115 pathway, functionally similar to the *NXT1*-*NXF1*-mediated ubiquitous bulk mRNA export pathway,

116 but involving testis-enriched *NXT2* as the key player and *NXF2* and *NXF3* as testis-specific
117 interaction partners (Figure 1e).

118 To corroborate the proposed direct interaction of *NXT2* with *NXF2* and *NXF3*, we performed co-
119 immunoprecipitation (Co-IP) of HA-tagged *NXT2* with FLAG-tagged *NXF2* (Figure 1g) or FLAG-
120 tagged *NXF3* (Figure 1h) overexpressed in HEK293T cells. *NXF2* and *NXF3* were only detectable
121 in Western blots when *NXT2* was co-expressed, demonstrating a specific and direct interaction
122 of both proteins with *NXT2* also *in vitro*.

123 *NXT2* interacts with *NXF2* and *NXF3* through NTF2-like domains

124 *NXF1*, *NXF2*, and *NXF3* share very similar protein structures, consisting of an RNA recognition
125 motif domain (RRM domain) and a nuclear transport factor 2-like domain (NTF2-like
126 domain/NTF2LD). *NXF2* also shares a C-terminal nuclear pore complex binding domain with
127 *NXF1*, which is absent in *NXF3* (Supplementary Figure 2). To characterize the interaction of *NXT2*
128 with testis-specific *NXF2* and *NXF3* in detail, we queried which of these domains mediates the
129 binding to *NXT2*. Accordingly, we generated FLAG-tagged expression constructs of *NXF2* and
130 *NXF3*, lacking the NTF2-like domains or the RRM domains (Figure 2a), overexpressed them in
131 HEK293T cells (Supplementary Figure 3a), and performed Co-IP analyses. Binding to *NXT2* was
132 abolished when the NTF2-like domain was deleted in *NXF2* (Figure 2b). However, *NXF2* lacking
133 the RRM domain was still able to bind to *NXT2* (Figure 2c). In line, deletion of the NTF2-like
134 domain in *NXF3* (Figure 2d; Supplementary Figure 3b) inhibited binding to *NXT2* (Figure 2e),
135 whereas deletion of the RRM domain (Figure 2d; Supplementary Figure 3b) did not affect binding
136 capacity (Figure 2f). Besides, a C-terminally truncated *NXT2*, lacking the last six amino acids but
137 containing the NTF2-like domain (Supplementary Figure 4a) was still able to bind to both *NXF2*
138 (Supplementary Figure 4b) and *NXF3* (Supplementary Figure 4c). These data show that the
139 binding of *NXT2* and *NXF2/3* depends on the NTF2-like domain of the respective interaction
140 partners, while the RRM domain is dispensable *in vitro*.

141 *Deleterious variants in NXT2 are associated with azoospermia and loss of germ cells*

142 Since *NXT2* has a testis-enriched expression profile and may have evolved testis-specific
143 functions, we next addressed the question of whether impaired *NXT2* function in the human testis
144 impairs sperm production and causes male infertility. A first indication comes from population
145 genetic data: *NXT2*'s LoF observed/expected (o/e) fraction is zero with a LoF o/e upper bound
146 fraction (LOEUF) of 0.51 (gnomAD, v2.1.1, not yet available for v.4.1, Supplementary Table 3).
147 Such low o/e fractions are rare and specify intolerance to LoF variants, supporting an important
148 biological relevance of the encoded protein and selective pressure on genetic variants affecting
149 protein function. Indeed, *TEX11* is one such X-chromosomal gene with an o/e fraction of zero and
150 one of the best established male infertility genes^{13,14}. We, therefore, screened for potentially
151 deleterious genetic variants in *NXT2* in exome/genome sequencing data of more than 2,700 well-
152 characterized infertile men from the Male Reproductive Genomics (MERGE) cohort. Focusing on
153 rare (minor allele frequency [MAF] ≤ 0.001 , gnomAD v2.1.1) LoF or high impact missense variants
154 (with CADD score ≥ 10) and copy number variations in *NXT2*, we identified two infertile men.
155 Subject M3065 showed a hemizygous single nucleotide duplication (c.354dup), resulting in a
156 premature stop codon p.(Asp119*) (Figure 3a, Supplementary Table 3), and M2004 the single
157 nucleotide substitution c.268G>T resulting in the substitution of an alanine to serine at position
158 90 in the NTF2-like domain of the *NXT2* protein sequence (p.(Ala90Ser)) (Figure 3a,
159 Supplementary Table 3). In addition, a further LoF variant in *NXT2* was identified in exome data
160 of a second cohort of 667 infertile men from Nijmegen/Newcastle¹⁵. The respective subject
161 RU00584 was positive for a large deletion encompassing the entire *NXT2* gene (Figure 3a,
162 Supplementary Table 3). This variant had been listed in the supplemental data of a recent
163 publication without presenting clinical or functional data¹⁵. Andrological evaluation in all three men
164 concordantly described azoospermia and elevated FSH levels (Supplementary Table 4),
165 indicating impaired spermatogenesis.

166 To investigate the impact of disturbed *NXT2* function on testicular germ cell development, we
167 detailedly analyzed the subjects' clinical and testicular phenotypes, as well as the cellular

168 expression pattern of *NXT2* in the human testis. Periodic acid-Schiff (PAS) staining of testicular
169 sections from all three cases, derived from testicular biopsies, revealed a common phenotype
170 characterized by seminiferous tubules predominantly lacking germ cells (Sertoli cell-only, SCO,
171 HP:0034299, Figure 3b). To reinforce these histological findings, we performed
172 immunohistochemical staining for the germ cell/spermatogonial stem cell marker MAGEA4.
173 Interestingly, only M3065 had a few focal seminiferous tubules with spermatogonia and
174 spermatocytes (Figure 3c), but no sperm could be retrieved by testicular sperm extraction (TESE).
175 In contrast, MAGEA4 staining was negative in M2004 and RU00584, although a few
176 morphologically abnormal sperm were detected in a TESE-derived testicular cell suspension in
177 RU00584. Due to their abnormal appearance, the sperm were deemed unsuitable for ICSI
178 (Supplementary Table 4).

179 Published scRNA-seq datasets^{16,17} of the human fetal male germ cells and adult testis depict a
180 strong expression of *NXT2* not only in adult but also in fetal germ cells (Figure 3d), supporting a
181 function of *NXT2* already at fetal/embryonic stages of germ cell development. In addition to germ
182 cells, in adult testicular tissue, *NXT2* was also expressed in somatic Sertoli cells¹⁷⁻¹⁹, indicating
183 not only a developmental, but also a cell type-specific function of *NXT2* in testicular tissue
184 (Figure 3d).

185 To address the genetic and functional impact of the identified variants in *NXT2*, we performed co-
186 segregation analyses within the families and in-depth functional characterization of the variants
187 at the protein level. M3065 shared the *NXT2* LoF variant c.354dup p.(Asp119*) with two further
188 infertile male siblings with azoospermia (M3065B1/B3). The variant was inherited from the
189 heterozygous female parent and was absent in fertile male relatives, thus co-segregating with
190 azoospermia/infertility (Figure 4a). Other genetic causes were excluded by filtering for shared rare
191 (MAF ≤ 0.01), coding variants in the exome data of all affected family members that were absent
192 in unaffected male family members. In this shared variant analysis, additional rare variants,
193 predicted to result in protein sequence alterations and additionally co-segregating with the

194 phenotype, were identified exclusively in genes that were expressed in other tissues or
195 ubiquitously expressed (Supplementary Table 5).

196 The c.354dup variant introduces a premature stop codon at position 119 of the *NXT2* open
197 reading frame, likely resulting in the degradation of the mutant mRNA by nonsense mediated
198 decay (NMD). If, however, the transcript escapes NMD, the truncated protein would lack 78 C-
199 terminal amino acids and thus most of the NTF2-like domain (Figure 4b). Overexpression of HA-
200 tagged *NXT2* c.354dup in HEK293T cells resulted in the complete absence of the truncated
201 protein according to Western blot analysis (Figure 4c), arguing against the expression of a stable
202 truncated protein. To corroborate the suspected absence of *NXT2* in the subject's testicular
203 tissue, we performed immunohistochemical staining for *NXT2* using an antibody that is directed
204 against an *NXT2* protein region that would be present in the truncated protein (Supplementary
205 Table 1). Indeed, no *NXT2*-specific staining could be detected in the subject's Sertoli cells, which
206 were clearly assignable by positive staining for the Sertoli cell marker SOX9. In contrast, a tissue
207 with complete spermatogenesis displayed positive staining for *NXT2* in spermatogonia and Sertoli
208 cells (Figure 4d).

209 RU00584 was previously described as carrying a deletion of *NXT2* identified by exome
210 sequencing¹⁵, but this variant had not been not prioritized for follow-up at that time. Analysis of
211 subsequently produced genome sequencing data indicated that the subject presents a 42 kb
212 large deletion on the X chromosome encompassing the entire *NXT2* gene. Interestingly, the
213 deletion occurred *de novo*, as it was not detected in the subject's parents, providing further genetic
214 evidence that the variant is pathogenic (Figure 5a). Fittingly, no *NXT2*-specific staining could be
215 detected in Sertoli cells, identified by SOX9-positive staining, confirming the expected absence
216 of *NXT2* *in vivo* (Figure 5b).

217 The third *NXT2* variant identified in M2004, c.268G>T, affects the 5'-end nucleotide of *NXT2* exon
218 four (Supplementary Figure 5a). As this variant might affect splicing, we performed a minigene
219 assay to analyze the effect on the recognition of the respective splice site *in vitro*. In contrast to

220 the wildtype, the mutant *NXT2* minigene revealed two distinct splice products. In addition to the
221 clearly visible normally spliced transcript, a faint signal was detected corresponding to an
222 aberrantly spliced transcript lacking exon four. Skipping of this exon would result in a shift of the
223 open reading frame and subsequent insertion of a premature stop codon (c.268G>T r.268_412del
224 p.(Ala90Serfs*13)) (Supplementary Figure 5b). The predicted amino acid substitution resulting
225 from c.268G>T affects the alanine residue at position 90, which is highly conserved in orthologous
226 proteins (Supplementary Figure 5c) and positioned in a central protein domain, as indicated by
227 the AlphaFold2 model (Supplementary Figure 5d). Because the residue is located in the NTF2-
228 like domain, which is crucial for binding to NXF2 and NXF3, we next analyzed whether the amino
229 acid substitution affects protein stability or binding to NXF2 or NXF3. When overexpressing
230 mutant *NXT2* in HEK293T cells, the protein expression level was comparable to the wildtype
231 (Supplementary Figure 5e) and, in Co-IP, binding of mutant *NXT2* to NXF2 (Supplementary
232 Figure 5f) and NXF3 (Supplementary Figure 5g) was unaffected. In addition, *NXT2* staining was
233 present in SOX9-positive Sertoli cells in the subject's testis (Supplementary Figure 5h).
234 Accordingly, no clear functional link could be established between this missense variant and the
235 proband's Sertoli cell-only phenotype.

236 *An NXF3 variant leads to oligoasthenoteratozoospermia*

237 To unravel whether the testis-expressed binding partners of *NXT2*, the nuclear export factor
238 proteins NXF1, NXF2, and NXF3, are also important for male fertility, we screened the
239 exome/genome data of the MERGE and Nijmegen/Newcastle cohorts for rare, potentially
240 deleterious variants in *NXF1*, *NXF2*, and *NXF3* using the same filtering criteria as outlined above
241 for *NXT2*.

242 A potentially deleterious variant was detected only in *NXF3*. One man with infertility (M2799)
243 identified in the MERGE cohort was positive for the hemizygous stop-gain variant c.826G>T
244 p.(Gly276*). With a LoF o/e fraction of 0.33 and a LOEUF of 0.6 (gnomAD, v2.1.1)
245 (Supplementary Table 3) also *NXF3* indicates a reduced tolerance to LoF variants in the general
246 population. The variant is located in exon nine of *NXF3* (Figure 6a) and would lead to a protein

247 lacking the NTF2-like domain (Figure 6b) if the mutant transcript escaped NMD. The variant was
248 inherited from the heterozygous female parent and was not identified in two fertile male relatives
249 (Figure 6c). No further high-impact variants in genes expressed in the testis were present in the
250 proband's exome. In Western blot analyses of lysates overexpressing the mutant protein, a
251 ~30 kDa smaller protein (Figure 6d) compared to the wildtype protein was detected. This
252 truncated protein was unable to bind to *NXT2*, as demonstrated by Co-IP (Figure 6e). Thus, even
253 if the mutant transcript would escape NMD, the stop-gain variant would result in an abolished
254 interaction with *NXT2*.

255 In contrast to the subjects with *NXT2* variants, who were concordantly azoospermic, M2799 had
256 extreme oligozoospermia (<2 million total sperm count) and mostly immotile sperm in his
257 ejaculate (≥85 %) in two independent semen samples. Sperm morphology was not assessed
258 during routine semen analysis. The striking difference in the phenotypes observed in men with
259 *NXT2* variants compared to the phenotype of M2799 with the *NXF3* variant is in line with the
260 different expression profiles of the two genes. In contrast to *NXT2*, *NXF3* is not expressed in male
261 fetal germ cells, according to published scRNA-seq datasets (Supplementary Figure 6a). Notably,
262 within the adult testis, *NXF3* mRNA is present in Sertoli cells and spermatids (Supplementary
263 Figure 6b), indicating a function of the *NXT2*-*NXF3* heterodimer at later stages of
264 spermatogenesis.

265 To analyze the localization of *NXF3* in sperm, we performed immunofluorescence staining using
266 an *NXF3*-specific antibody (Supplementary Figure 1c/d; Supplementary Table 1). In sperm from
267 a control donor, *NXF3* localized to the midpiece, more specifically to the centriole/connecting
268 piece (Figure 6f). In contrast, no *NXF3*-specific staining was detected in M2799's sperm,
269 indicating the absence of protein expression *in vivo*. To further screen for morphological sperm
270 abnormalities that could potentially explain the observed sperm immotility, we stained the sperm
271 with a Tubulin-specific antibody, which specifically highlights the flagellum, and with Mitotracker,
272 staining mitochondria in the midpiece (Figure 6f). Interestingly, in M2799's sperm, Mitotracker-
273 specific staining was not detectable, suggesting a midpiece defect/malformation or mitochondrial

274 dysfunction, leading to the observed impairment of sperm motility. In summary, the man with the
275 *NXF3* LoF variant had quantitatively and qualitatively severely impaired sperm production.

276 **Discussion**

277 In this study, we demonstrate that testis-enriched *NXT2* is indispensable for normal
278 spermatogenesis in humans by identifying two *NXT2* variants that abolish protein expression in
279 infertile men with azoospermia. Both subjects share a testicular phenotype of predominant Sertoli
280 cell-only, *i.e.*, absence of germ cells, which we link to the absence of *NXT2* in the testicular tissue.
281 One of the variants co-segregates with the infertility in the family, while for the second variant a
282 *de novo* occurrence was demonstrated, strengthening the genetic evidence for the association
283 with the observed phenotype¹⁵. Indeed, *NXT2* had not yet been associated with any disease and
284 only three heterozygous LoF variants in *NXT2*, identified in females, are present in the newest
285 gnomAD population database of >800,000 individuals (v4.1.0), indicating intolerance to LoF
286 variants, selective pressure, and/or incompatibility with heritability . From a clinical perspective,
287 *NXT2* is a strong candidate gene for male infertility due to azoospermia but the identification of
288 additional patients harboring variants in *NXT2* is necessary to firmly establish a clinically valid
289 gene-disease relationship.

290 Since germ cells are largely absent in affected men's testes, we propose that *NXT2* has a critical
291 function either in somatic Sertoli cells, being crucial for orchestrating spermatogenesis by
292 maintaining the spermatogonial stem cell niche and providing essential growth factors²⁰, and/or
293 in first steps of germ cell development, as evidenced by the enriched expression of *NXT2* in fetal
294 male germ cells.

295 In contrast to *NXT1*, *NXT2* has undergone adaptive selection during evolution¹¹ and displays a
296 testis-enriched expression only in primates, whereas the protein is ubiquitously expressed in
297 rodents. These different evolutionary fates already point towards a tissue-specific novel function
298 of *NXT2* restricted to the primate testis. This is supported by our finding that the absence of *NXT2*
299 in humans is associated with impaired spermatogenesis, whereas in mice *Nxt2* has been
300 demonstrated to be dispensable for fertility²¹.

301 Our data also support an involvement of *NXT2* in the export of bulk mRNA through the nuclear
302 pore, as we demonstrate not only an interaction with *NXF1*, part of the well-characterized *NXT1*-
303 *NXF1* export factor complex⁵, but also with the nucleoporins *NUP93* and *NUP214*. *NUP214*
304 contains phenylalanine-glycine (FG)-repeats that are essential for binding to *NXF* proteins²² and
305 both *NUPs* are involved in the transport of *RNPs* through the nuclear pore²³. In addition to the
306 evolutionarily acquired adaptations of *NXT2*, both the absence of *NXT1* from the interactome and
307 the severe phenotype observed in men with *NXT2* variants suggest that, in humans, the cellular
308 function of *NXT2* cannot be compensated by *NXT1*, pointing towards testis-specific *NXT2*-*NXF*
309 dependent processes.

310 In addition to the ubiquitously expressed *NXF1*, humans encode four additional *NXF* genes
311 (*NXF2-NXF5*), all of which are located on the X chromosome and display mainly tissue-specific
312 expression patterns⁷. *NXF2* shares an overall similar protein structure with *NXF1*, reveals a testis-
313 specific expression, and associates with mRNA *in vitro*⁷. The mouse ortholog of *NXF2* localizes
314 to the nucleus or the nuclear periphery of germ cells, supporting a function in RNA export through
315 the nuclear pore complex²⁴. *Nxf2* knockout mice revealed an age-dependent depletion of
316 spermatogonial stem cells and male infertility²⁵, and a crucial function in regulating germ cell
317 development was proposed. However, as no men harboring potentially deleterious variants in
318 *NXF2* have been identified yet, it remains to be seen whether loss of *NXF2* will also results in
319 human male infertility.

320 Mammalian *NXF3* lost its nuclear pore complex binding ability⁷ but gained an additional binding
321 site for *XPO1* (also called *CRM1*), an exportin that facilitates translocation through the nuclear
322 pore complex²⁶. Based on the tissue-specific expression of *NXF3* in the testis, it has been
323 speculated that the *NXF3*-*XPO1* complex mediates the transport of specific *RNAs*²⁶. We present
324 genetic and functional data indicating that human *NXT2* binds to *NXF3* in the testis and that
325 abrogation of *NXF3* function leads to impaired sperm development at later stages of
326 spermatogenesis. In contrast to *NXT2*, *NXF3* is not expressed in fetal male germ cells but at later
327 stages of spermatogenesis¹⁹, suggesting that *NXF3* is dispensable for fetal functions of the *NXT2*-

328 mediated RNA transport but is likely crucial during adult spermatogenesis. Fittingly, we observed
329 that NXF3 localizes to the sperm midpiece in sperm from a control individual, while being absent
330 in the subject hemizygous for the *NXF3* variant. Of note, and similar to *NXT2*, knockout of the
331 *NXF3* ortholog in mice does not impact spermatogenesis²⁷, again pointing towards different
332 evolutionary fates of the human and mouse genes. The cargos of NXF3-mediated transport in
333 mammals have not been elucidated yet and XPO1 was not identified as part of the *NXT2*
334 interactome in this study. Hence, it remains to be clarified whether the infertility in the *NXF3* LoF
335 subject is a consequence of impaired mRNA export at later stages of spermatogenesis or a
336 consequence of other NXF3 related functions.

337 Examples of other RNA nuclear export-independent functions of NXF proteins have already been
338 described for mammalian NXF2, which is involved in cytoplasmic mRNA dynamics by interacting
339 with motor proteins such as KIF17²⁸. In addition, expression of more than one NXF protein is also
340 known from other eukaryotic lineages, including *Caenorhabditis elegans* and *Drosophila*
341 *melanogaster*, and interestingly this diversification occurred independently assuming that these
342 NXF variants might also have evolved novel molecular functions, not directly related to mRNA
343 export²⁹ as we suggest for human NXF2/3. Indeed, in *Drosophila melanogaster*, one of the NXF
344 proteins (*Drosophila* Nxf2) triggers co-transcriptional repression of transposons in germ cells in a
345 Piwi-dependent manner³⁰. Further, the *Drosophila* NXF3 was shown to export piRNA precursors
346 and guide them to the nuage, a germ cell specific granule, where they are processed into mature
347 piRNAs, which are important for protecting genome integrity by silencing transposable
348 elements^{31–33}.

349 Besides nuclear export factors, we have also identified SPATA5 and SPATA5L1, which initiate
350 the cytoplasmic pre-60S maturation cascade within ribosome biogenesis and trigger the release
351 of shuttling factors^{34,35}, as part of the *NXT2* interactome. Since SPATA5 directly processes the
352 pre-60S particle after transport through the nuclear pore complex and also interacts with
353 nucleoporins³⁶, the interaction with *NXT2* could indicate an involvement of *NXT2* in the export of
354 ribosomal subunits. Of note, a testis-specific ribosome with a specialized nascent peptide exit

355 tunnel facilitating translation during sperm formation has recently been described, and deletion of
356 this ribosome has been associated with defective sperm formation and subfertility in mice³⁷.

357 In summary, we introduce *NXT2* as a strong candidate gene for male infertility and demonstrate
358 that the encoded protein is the key player in adult human testis bulk RNA nucleocytoplasmic
359 transport by interacting with the RNA export factor NXF1 and the nuclear pore complex. *NXT2*
360 also interacts with the human testis-specific nuclear export factor proteins NXF2 and NXF3 and
361 ribosome biogenesis factors giving rise to cellular functions independent of nucleocytoplasmic
362 mRNA transport and/or cargo specificity in the human testis. It remains to be elucidated which
363 specific cargos are transported in *NXT2* mediated export.

364 **Methods**

365 *Ethical approval*

366 All persons included in the study gave written informed consent for the analysis of their donated
367 material and the evaluation of their clinical data compliant with local requirements. The use of
368 testicular tissue for pulldown analysis and the MERGE study protocol were approved by the
369 Münster Ethics Committees/Institutional Review Boards (Ref. No. Münster: 2012-555-f-S and
370 2010-578-f-S). Semen samples were provided by normozoospermic donors with prior written
371 consent according to the protocols approved by the Ethics Committee of the Ärztekammer
372 Westfalen-Lippe and the Medical Faculty Münster (4INie, 2021-402-f-S). The study protocol of
373 the Radboudumc outpatient clinic and the Newcastle upon Tyne Hospitals NHS Foundation Trust
374 (Newcastle, UK) was approved by the respective Ethics Committees/Institutional Review Boards
375 (Nijmegen: NL50495.091.14 version 5.0, Newcastle: REC ref. 18/NE/0089). All procedures were
376 in accordance with the Helsinki Declaration of 1975. Subjects' identifiers are not known to anyone
377 outside of the research groups.

378

379 *Lysis of human testicular tissue*

380 Adult human testicular tissue derived from surgery of three subjects with obstructive azoospermia
381 (OA) (pooled) and one transgender person, who still had full spermatogenesis in testicular biopsy
382 despite of the hormonal treatment, was stored at -80 °C prior homogenization with the
383 TissueLyser LT (QIAGEN, Hilden, Germany) for 6 min with a 5 mm Stainless Steel Bead
384 (QIAGEN, Hilden, Germany) in Pierce IP lysisbuffer (#87787 [Thermo Scientific™, Waltham,
385 USA]; 50 mM Tris-HCl, 1 % Triton X-100, 5 mM EDTA, 150 mM NaCl, 0.2 mM PMSF, 1 mM DTT,
386 1x protease inhibitor cocktail). The samples were incubated on ice for 15 min and centrifuged at
387 4 °C and 14000 rcf for 10 min. The supernatant was immediately used for pulldown experiments.

388 *Pulldown of native proteins from testicular lysates and preparation of samples for mass*
389 *spectrometry*

390 Dynabeads Protein-G (Thermo Scientific™, Waltham, USA) were incubated with 5 µg of specific
391 NXT2 and IgG antibodies (Supplementary Table 1) for 90 min at 4 °C. To perform the pulldown,
392 the coupled beads were incubated with testicular lysate (~80 mg) at 4 °C overnight. Of the 120 µl
393 sample, 20 µl were used for subsequent Western blot analysis to check for efficiency of the
394 pulldown and 50 µl were washed with 50 mM Tris-HCl (pH 8) three times. The beads were dried
395 and stored at -80 °C. Four independent replicates pulled down with NXT2 (3 samples from the
396 transgender person tissue lysate, 1 sample of pooled tissue lysates from men with obstructive
397 azoospermia, OA [HP:0011962]) and two control replicates pulled down with IgG (2 samples from
398 transgender person tissue lysate) were sent for mass spectrometry analyses.

399 *LC-ESI-MS/MS Analysis*

400 The LC-ESI-MS/MS analyses were performed in the Proteomics Facility at the University of Turku
401 on a nanoflow HPLC system (Easy-nLC1200, Thermo Scientific™, Waltham, USA) coupled to
402 the Q Exactive HF (Thermo Fisher Scientific, Bremen, Germany) equipped with a nano-
403 electrospray ionization source. Peptides were first loaded on a trapping column and subsequently
404 separated inline on a 15 cm C18 column (75 µm x 15 cm, ReproSil-Pur 3 µm 120 Å C18-AQ, Dr
405 Maisch HPLC GmbH, Ammerbuch-Entringen, Germany). The mobile phase consisted of water
406 with 0.1 % formic acid (solvent A) and acetonitrile/water (80:20 (v/v)) with 0.1 % formic acid
407 (solvent B). A 70 min gradient was used to eluate peptides (60 min from 6 % to 39 min solvent B
408 and in 2 min from 39 % to 100 % of solvent B, followed by 8 min wash stage with solvent B). MS
409 data was acquired automatically by using Thermo Xcalibur 4.1 software (Thermo Scientific™,
410 Waltham, USA). An data dependent acquisition method repeated cycles of one MS1 scan
411 covering a range of 350–1750 m/z followed by HCD fragment ion scans (MS2 scans) for the 10
412 most intense peptide ions from the MS1 scan. Two-sided t-test on protein abundance values was
413 used to identify significant (p<0.05) interaction partners of NXT2 compared to IgG.

414 *Gene Ontology Analysis*

415 Gene ontology analysis (<http://geneontology.org>)^{38,39} was performed for all genes encoding
416 proteins significantly enriched in the *NXT2* pulldown compared to IgG (Figure 1a) (for “biological
417 processes” and “homo sapiens”) and processed with PANTHER
418 (<https://pantherdb.org/webservices/go/overrep.jsp>)⁴⁰ (annotation dataset: “GO biological
419 processes complete”, test type: ‘Fisher’s Exact’, Correction: “Bonferroni”, showing results with P
420 <0.05). GO terms were then processed with Revigo62 (<http://revigo.irb.hr/>)⁴¹ using the P-value
421 and a medium (0.7) list setting (obsolete GO terms were removed, species “homo sapiens”,
422 “SimRel” semantic similarity measure). The Revigo Table was exported and -log₁₀(P-value) of
423 representative GO terms (classed as representation: ‘null’) were plotted with CirGO.py⁶³⁴² for
424 visualization of the 2-tiered hierarchy of GO-terms.

425 *STRING interaction analysis*

426 To identify protein clusters within the significantly enriched proteins, a STRING functional protein
427 association analysis was carried out⁴³. There was no filtering for active interaction sources and
428 line thickness indicates the confidence of the interaction. K-mean clustering with a given number
429 of three clusters was executed.

430 *Cloning of cDNA constructs*

431 Human adult testis RNA (BioCat, Heidelberg, Germany) was converted to cDNA using the
432 GoScript™ Reverse Transcriptase system (Promega, Madison, USA) according to the
433 instructions of the manufacturer. Amplification of human cDNAs encompassing the entire open
434 reading frame of *NXT2* (NM_018698.5), *NXF2* (NM_022053.4) and *NXF3* (NM_022052.2) was
435 performed with PrimeSTAR Max polymerase (Takara Bio, Kusatsu, Japan) and PCR products
436 were cloned into the mammalian expression vector pcDNA3.1(+) (Genscript, Leiden, NL). Using
437 phosphorylated primers, an HA-tag was cloned to the N-terminus of *NXT2* and a FLAG-tag was
438 added to the C-terminus of *NXF2* and N-terminus of *NXF3*, respectively. Deletions of respective
439 protein domains and addition of Kozac-sequences to the 5'-end of *NXF2* and *NXF3* constructs
440 were introduced to increase expression by PCR using phosphorylated primers and blunt end

441 ligation of PCR products. All constructs were verified by Sanger sequencing. Primer sequences
442 can be found in Supplementary Table 6.

443 *Mutagenesis of constructs*

444 Point mutations identified in infertile men were introduced using site-directed-mutagenesis
445 according to manufacturer's instructions (QuikChange II XL Site-Directed Mutagenesis Kit,
446 Agilent Technologies, Santa Clara, USA). The *NXT2* LoF variant (c.354dup), the *NXT2* missense
447 variant (c.268G>T) and the *NXF3* LoF variant (c.826G>T) were introduced in wildtype (WT) *NXT2*
448 and WT *NXF3* cDNA clones, respectively. Successful mutagenesis was verified by Sanger
449 sequencing (see Supplementary Table 6 for primer sequences).

450 *Culture and transfection of HEK293T cells*

451 Human embryonic kidney (HEK) 293T cells were cultured in Dulbecco's Modified Eagle Medium
452 (DMEM, Sigma-Aldrich, Munich, Germany), supplemented with 10 % fetal calf serum (FCS) and
453 1 % penicillin-streptomycin. The cells were maintained in T75 cell culture flasks at 37 °C and 5 %
454 CO₂. Passaging was accomplished twice a week and cells were used up to passage 20. Per well
455 400,000 cells were seeded into 6-well plates and transfected the following day using K2
456 transfection reagent (Biontex Laboratories GmbH, München, Germany) with either 2 µg (single
457 plasmid transfections) or 4 µg plasmid DNA (co-transfections). For co-transfections of two
458 constructs, the amounts of transfected DNA were harmonized according to the length of the
459 fragments on cDNA level. A medium change was performed 6 h after transfection and protein
460 lysates were prepared 48 h after transfection. Transfection and subsequent analyses were
461 performed in independent triplicates.

462 *Lysis of HEK293T cells*

463 Transfected HEK293T cells were detached using ice-cold phosphate buffered saline (PBS),
464 followed by 5 min of centrifugation at 4 °C and 2000 rcf. Lysis was performed by thorough manual
465 pipetting. Different lysis buffers were used for standard lysates (25 mM HEPES, 100 mM NaCl,
466 1 mM CaCl₂, 1 mM MgCl₂, 1 % TritonX-100, 1x protease inhibitor cocktail) and Co-IP samples

467 (0.025 M Tris, 0.15 M NaCl, 0.001 M EDTA, 1 % NP-40, 1 % glycerol, 1x protease inhibitor
468 cocktail). After an incubation of 15 min on ice and centrifugation for 15 min at 4 °C and 13000 rcf
469 supernatants were separated. Samples were either directly denatured and used for Western blot
470 or directly taken for Co-IP experiments.

471 *Co-IP of overexpressed proteins*

472 HA-coupled magnetic beads (Thermo Scientific™, Waltham, USA) were used for Co-IP
473 experiments according to manufacturer's instructions. The IP of HEK293T cell lysates was carried
474 out 30 min at room-temperature in a rotator, followed by three (NXT2-NXF3) or nine (NXT2-NXF2)
475 washes with 0.05 % TBS-T and a final wash with H₂O. An acidic elution (elution buffer pH 2.0)
476 was performed for 8 min prior pH neutralization. For each approach both co-expressed proteins
477 were also separately transfected and used as positive and negative controls.

478 *Western blot*

479 65 µl lysate were mixed with 25 µl 4x Laemmli (Bio-Rad, Hercules, USA) and 10 µl DTT and
480 denatured at 95 °C for 10 min. Samples were separated on Mini-PROTEAN® TGX StainFree™
481 Precast gels (Bio-Rad, Hercules, USA) and transferred to a PVDF membrane using a Trans-blot
482 Turbo Mini Transfer Pack kit (Bio-Rad, Hercules, USA) according to manufacturer's instructions.
483 Membranes were blocked with 5 % milk powder in 0.025 % TBS-Tween (TBS-T) solution for
484 30 min at room temperature (RT) prior to primary antibody incubation (Supplementary Table 1)
485 overnight at 4 °C. After washing, a peroxidase-conjugated secondary antibody incubation (2 h,
486 RT, Supplementary Table 1) followed. Chemiluminescence was detected with the Clarity™
487 Western ECL Substrate kit (Bio-Rad, Hercules, USA) and the ChemiDoc MP Imaging System
488 (BioRad, Hercules, USA). To assess and confirm the molecular weights of analyzed proteins, a
489 PageRuler™ plus prestained protein ladder (Thermo Scientific, Waltham, USA) was used.

490 *Study cohorts*

491 The Male Reproductive Genomics (MERGE) cohort included data of 2,703 men (2,629 with
492 exome and 74 with genome sequencing) mainly recruited in the Centre of Reproductive Medicine

493 and Andrology (CeRA) in Münster with various infertility phenotypes. Most men of this cohort had
494 azoospermia (N = 1,622, HP:0000027) or severely reduced sperm counts: N = 487 with
495 cryptozoospermia (sperm only identified after centrifugation of the ejaculate, HP:0030974);
496 N = 168 with extreme oligozoospermia (total sperm count <2 million, HP:0034815); N = 85 with
497 severe oligozoospermia (sperm count <10 million, HP:0034818). History of oncologic diseases,
498 including testicular tumors, as well as numerical chromosomal aberrations, such as Klinefelter
499 syndrome (karyotype 47,XXY) and Y-chromosomal AZF-deletions, led to an exclusion. Likely
500 pathogenic monogenic causes for the infertility phenotype have already been described in about
501 8 % of cases¹⁴.

502 One further subject with a deletion of the entire *NXT2* gene was identified among the cohort of
503 677 infertile men from Nijmegen/Newcastle and the respective variant has already been
504 mentioned in the Supplementary data in a recent publication¹⁵.

505 *Exome sequencing, variant filtering, and validation of sequence variants*

506 Sequencing for the MERGE cohort has been described previously⁴⁴. In brief, genomic DNA was
507 extracted from peripheral blood leukocytes via standard methods. For exome sequencing of the
508 MERGE cohort, the samples were prepared and enrichment was carried out according to the
509 protocol of either Agilent's SureSelectQXT Target Enrichment for Illumina Multiplexed
510 Sequencing Featuring Transposase-Based Library Prep Technology (Agilent) or Twist
511 Bioscience's Twist Human Core Exome. To capture libraries, Agilent's SureSelect Human All
512 Exon Kits V4, V5 and V6 or Twist Bioscience's Human Core Exome plus RefSeq spike-in and
513 Exome 2.0 plus comprehensive spike-in were used. For whole genome sequencing of samples
514 from the MERGE cohort, sequencing libraries were prepared according to Illumina's DNA PCR-
515 Free library kit. For multiplexed sequencing, the libraries were index tagged using appropriate
516 pairs of index primers. Quantity and quality of the libraries were determined with the ThermoFisher
517 Qubit, the Agilent TapeStation 2200, and Tecan Infinite 200 Pro Microplate reader, respectively.
518 Sequencing was performed on the Illumina NextSeq 500 System, the Illumina NextSeq 550
519 System, or the NovaSeq 6000 System, using the NextSeq 500/550 V2 High-Output Kit (300

520 cycles), or the NovaSeq 6000 S1 and S2 Reagent kits v1.5 (200 cycles), respectively. After
521 trimming of remaining adapter sequences and primers with Cutadapt v1.15⁴⁵, reads were aligned
522 against GRCh37.p13 using BWA Mem v0.7.17⁴⁶. Base quality recalibration and variant calling
523 were performed using the GATK toolkit v3.8⁴⁷ with haplotype caller according to the best practice
524 recommendations. For more recent samples and whole genome samples Illumina Dragen Bio-IT
525 platform v4.2 was used for alignment and variant calling. Both pipelines use GRCh37.7.p13 as
526 reference genome. Resulting variants were annotated with Ensembl Variant Effect Predictor⁴⁸.
527 Exome/genome data were screened for rare (minor allele frequency [MAF] ≤ 0.001 in gnomAD
528 v2.1.1) variants in *NXT2*, *NXF1*, *NXF2*, and *NXF3* with a predicted effect on protein function,
529 including copy number variants, loss-of-function variants (frameshift, stop-gain, start-loss, splice
530 site) and amino acid substitutions with a CADD score ≥ 10 .

531 For the Nijmegen/Newcastle cohort, blood samples from probands and saliva samples from
532 parents were used to extract DNA using the QIAGEN® Genra® Puregene® DNA extraction kit
533 according to manufacturer's instructions (QIAGEN®, Venlo, NL). Samples were prepared and
534 enriched according to manufacturer's protocols of either Illumina's Nextera DNA Exome Capture
535 kit or Twist Bioscience's Twist Human Core Exome Kit for exome sequencing, samples submitted
536 for whole genome sequencing were prepared instead following the manufacturer's instructions
537 for the Illumina TruSeq DNA PCR-free® library preparation kit followed. All samples were
538 sequenced on a NovaSeq 6000 Sequencing System (Illumina, San Diego, USA). Following best
539 practices recommendations sequencing data was processed as described previously¹⁵. Briefly,
540 sequenced reads were aligned to the Genome Reference Consortium human assembly 38
541 (GRCh38/hg38) through BWA-MEM. Single nucleotide variations and small indels were identified
542 and quality-filtered using GATK's HaplotypeCaller v4.2.6.1⁴⁹. Copy number variation (CNV)
543 analysis of whole genome sequencing data was performed by combining Dysgu-sv⁵⁰ and GATK-
544 based CNVRobot (<https://github.com/AnetaMikulasova/CNVRobot>) with default parameters.
545 Afterwards, CNVs predicted to be *de novo* were inspected through IGV⁵¹.

546 All identified variants were verified by Sanger sequencing; for primer sequences, see
547 Supplementary Table 6. If available, segregation analyses were carried out with DNA from family
548 members. PCR products were purified and sequenced using standard protocols.

549 *Minigene assay*

550 To assess the impact on splicing of the missense variant c.268G>T p.(Ala90Ser) that affects the
551 first nucleotide of exon 4 in *NXT2*, an *in vitro* splicing assay based on a minigene construct was
552 performed. Primers flanking exon 4 of *NXT2* (Supplementary Table 6) were used to amplify the
553 region of interest from genomic DNA of M2004 as well as a human control sample by standard
554 PCR using 0.4 U of Phusion™ High-Fidelity DNA Polymerase (Thermo Scientific™, Waltham,
555 USA). PCR products were cloned into pENTR™/D-TOPO® (Thermo Scientific™, Waltham, USA)
556 according to manufacturer's instructions. Gateway cloning was performed using Gateway™ LR
557 Clonase™ Enzyme Mix (Thermo Scientific™, Waltham, USA) and pDESTsplice as destination
558 vector (pDESTsplice was a gift from Stefan Stamm (Addgene plasmid #32484))⁵². A transient
559 transfection with X-tremeGENE™ 9 transfection reagent (Sigma-Aldrich, St. Louis, USA) of
560 Human Embryonic Kidney cells, HEK293T293T Lenti-X (Clontech Laboratories, Inc., Mountain
561 View, USA) was carried out with mutant and wildtype *NXT2* minigenes. 24 h after transfection,
562 total RNA was extracted using the RNeasy Plus Mini Kit (QIAGEN, Hilden, Germany) and reverse-
563 transcribed into cDNA with the ProtoScript II First Strand cDNA Synthesis Kit (New England
564 Biolabs GmbH, Frankfurt am Main, Germany). Amplification of the region of interest was
565 performed using primers annealing to the rat insulin exons 3 and 4 that are part of the minigene
566 construct (Supplementary Table 6). PCR products were separated on a 2 % agarose gel, bands
567 were extracted using the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) and sequenced
568 (Supplementary Table 6). For better visualization, PCR products were additionally analyzed on a
569 4150 TapeStation System (Agilent Technologies, Santa Clara, USA).

570 *Period acid-Schiff staining of human testicular tissue*

571 Subjects M2004, M3065 and RU00584 underwent testicular biopsy, as indicated by diagnosis of
572 non-obstructive azoospermia (NOA) according to EAU guidelines^{53,54} with the aim of testicular

573 sperm extraction. After written informed consent, testicular biopsies were taken, immediately fixed
574 in Bouin's solution, and subsequently embedded in paraffin wax. Periodic acid-Schiff (PAS)
575 staining was carried out according to previously published protocols^{55,56}. In brief, sections were
576 dewaxed in solvent (ProTaq Clear, #4003011; Quartett Immunodiagnostika and Biotechnologie,
577 Berlin, Germany), rehydrated in a decreasing ethanol series and then incubated for 15 min in 1 %
578 periodic acid. After washing with dH₂O sections were incubated for 45 min with Schiff's reagent
579 (Roth, Karlsruhe, Germany). Histological evaluation was performed following score count
580 analysis⁵⁵. Images were taken using an Olympus BX41 bright-field microscope equipped with a
581 Leica DMC4500 camera.

582 *Histological staining of NXT2, SOX9, and MAGEA4 in subjects' testicular tissue*

583 For immunohistochemistry (IHC), deparaffinization was carried out using NeoClear (Merck,
584 Darmstadt, Germany) and rehydration was done in a graded ethanol-water series. Antigen
585 retrieval was performed at 90 °C in citrate buffer (pH 6) for 10 min. After 30 min of pre-blocking
586 with 25 % goat serum, the primary antibody (NXT2/SOX9/MAGEA4; Supplementary Table 1) was
587 applied and incubated in humidity chambers at 4 °C overnight. The secondary, biotinylated α-
588 rabbit and α-mouse (ab6012; ab5886; Supplementary Table 1) antibodies were applied and
589 incubated for 1 h at RT. Visualization was conducted using the avidin-biotin complex method for
590 45 min at RT (ABC solution - horseradish peroxidase (Vector Laboratories, Burlingame, USA))
591 followed by 3,3'-diaminobenzidine as substrate and counterstaining with hematoxylin. As a
592 negative control, isotype rabbit IgG was included instead of the primary antibody in corresponding
593 concentrations and an omission control was performed only using 5 % BSA/TBS instead of the
594 primary antibody. Images were obtained using the PreciPoint O8 scanning microscope system.

595 *Immunocytochemistry of subject's sperm*

596 Cover slides were coated with poly-L-lysine and then incubated with approx. 2,000,000 control
597 sperm per slide after swim-up as previously described⁵⁷. As M2799's sperm are immotile, only
598 wash/centrifugation steps were performed. Fixation was done using 4 % PFA. After washing with
599 0.1 % Triton-X in PBS, cells were blocked with 1 % BSA in 0.1 % Triton-X in PBS. Primary

600 antibody incubation was done overnight in a humidity chamber at 4 °C with specific antibodies
601 against NXF3 and Tubulin (Supplementary Figure 1c/d, Supplementary Table 1). After washing,
602 DAPI (#D1306 (Thermo Scientific™, Waltham, USA)) and secondary antibodies (Supplementary
603 Table 1) were combined for 1 h incubation at RT (protected from light). In case of additional
604 staining with midpiece marker Mitotracker Red CMXRos (#9082 (Cell Signaling Technology,
605 Danver, USA), 500 nM), Mitotracker Red CMXRos was incubated for 1 h at RT after the
606 secondary antibody and DAPI were washed away with PBS-Triton-X. After mounting with Dako
607 Fluorescence Mounting Medium (#S3023 (Dako Denmark, Glostrup, Denmark)), slides were
608 dried at RT overnight and then stored at 4 °C prior imaging. Imaging was done using the Leica
609 DM2500 microscope and the Leica K3M camera.

610 *Prediction of NXT2 3D structure from AlphaFold2*

611 3D structures of NXT2 were predicted and edited using AlphaFold2^{58,59}. The short isoform of
612 NXT2 (NM_001242617.2) is depicted, as it is the only available version at the last date of
613 accession (04/24/24). Of note, for all other experiments and figures, the longer isoform of NXT2
614 (NM_018698.5) is used as the first exon which is only present in this isoform (NM_018698.5) is
615 testis expressed according to GTEx⁶⁰ (obtained from the GTEx Portal on 03/21/24).

616 **Statistics and Reproducibility**

617 In the mass spectrometry data analysis, statistical comparisons between IgG and NXT2 sample
618 groups were performed by two-sided Student's t-test. Experimental replicates were performed as
619 indicated in the respective figure legends. All reported variants were validated by Sanger
620 sequencing. The investigators were not blinded to allocation during experiments and outcome
621 assessment.

622 **Data availability**

623 Sequencing data of the MERGE study is available from the corresponding author upon request.
624 Access to this data is limited for each case and specific consent of the respective samples.
625 Sequencing data from the Nijmegen cohort have been deposited in the European Genome-

626 phenome Archive (EGA) under the accession code EGAS00001005417 [<https://ega->
627 archive.org/studies/EGAS00001005417] and will be made available upon reasonable request for
628 academic use and within the limitations of the provided informed consent by the corresponding
629 author upon acceptance. Every request will be reviewed by the Newcastle University Male
630 Infertility Genomics Data Access Committee; the researcher will need to sign a data access
631 agreement after approval. All other data supporting the findings of this study are available from
632 the corresponding author upon reasonable request. AlphaFold2 structure accession code for
633 *NXT2* is AF-Q9NPJ8-F1 [<https://alphafold.ebi.ac.uk/entry/Q9NPJ8>]. The mass spectrometry
634 proteomics data have been deposited the ProteomeXchange Consortium via the PRIDE⁶¹ partner
635 repository with the dataset identifier PXD052904 [<https://www.ebi.ac.uk/pride/>]. Genetic variants
636 identified in *NXT2* and *NXF3* were submitted to ClinVar (SCV005043065-SCV005043067;
637 [<https://www.ncbi.nlm.nih.gov/clinvar/>]). Source data are provided with this paper.

638 **References**

- 639 1. Palazzo, A. F., Qiu, Y. & Kang, Y. M. mRNA nuclear export: how mRNA identity features
640 distinguish functional RNAs from junk transcripts. *RNA Biol.* **21**, 1–12 (2024).
- 641 2. Lusk, C. P. & King, M. C. The nucleus: keeping it together by keeping it apart. *Curr. Opin.*
642 *Cell Biol.* **44**, 44–50 (2017).
- 643 3. Beck, M. & Hurt, E. The nuclear pore complex: understanding its function through structural
644 insight. *Nat. Rev. Mol. Cell Biol.* **18**, 73–89 (2016).
- 645 4. Viphakone, N. *et al.* TREX exposes the RNA-binding domain of Nxf1 to enable mRNA
646 export. *Nat. Commun.* **3**, 1–14 (2012).
- 647 5. Pacheco-Fiallos, B. *et al.* mRNA recognition and packaging by the human transcription–
648 export complex. *Nature* **616**, 828–835 (2023).
- 649 6. Liker, E., Fernandez, E., Izaurralde, E. & Conti, E. The structure of the mRNA export factor
650 TAP reveals a cis arrangement of a non- canonical RNP domain and an LRR domain.
651 *EMBO J.* **19**, 5587–5598 (2000).
- 652 7. Herold, A. *et al.* TAP (NXF1) Belongs to a Multigene Family of Putative RNA Export Factors
653 with a Conserved Modular Architecture. *Mol. Cell. Biol.* **20**, 8996–9008 (2000).
- 654 8. Suyama, M. *et al.* Prediction of structural domains of TAP reveals details of its interaction
655 with p15 and nucleoporins. *EMBO Rep.* **1**, 53–58 (2000).
- 656 9. Katahira, J. *et al.* The Mex67p-mediated nuclear mRNA export pathway is conserved from
657 yeast to human. *EMBO J.* **18**, 2593–2609 (1999).
- 658 10. Kang, Y. & Cullen, B. R. The human Tap protein is a nuclear mRNA export factor that
659 contains novel RNA-binding and nucleocytoplasmic transport sequences. *Genes Dev.* **13**,
660 1126 (1999).
- 661 11. Hu, J. *et al.* Genetic characterization of nuclear export factor NXT1 and its paralog NXT2
662 in primates and murine rodents. *Zoology (Jena)*. **151**, 126002 (2022).
- 663 12. Fribourg, S., Braun, I. C., Izaurralde, E. & Conti, E. Structural Basis for the Recognition of
664 a Nucleoporin FG Repeat by the NTF2-like Domain of the TAP/p15 mRNA Nuclear Export
665 Factor. *Mol. Cell* **8**, 645–656 (2001).
- 666 13. Yatsenko, A. N. *et al.* X-Linked TEX11 Mutations, Meiotic Arrest, and Azoospermia in
667 Infertile Men. *N. Engl. J. Med.* **372**, 2097–2107 (2015).
- 668 14. Wyrwoll, M. J. *et al.* Genetic Architecture of Azoospermia—Time to Advance the Standard
669 of Care. *Eur. Urol.* **83**, 452–462 (2023).
- 670 15. Oud, M. S. *et al.* A de novo paradigm for male infertility. *Nat. Commun.* **13**, 154 (2022).
- 671 16. Garcia-Alonso, L. *et al.* Single-cell roadmap of human gonadal development. *Nature* **607**,
672 540–547 (2022).
- 673 17. Liu, Z. *et al.* SMARTdb: An Integrated Database for Exploring Single-cell Multi-omics Data
674 of Reproductive Medicine. *Genomics. Proteomics Bioinformatics* **38**, e102870 (2024).
- 675 18. Zhao, L. Y. *et al.* Single-cell analysis of developing and azoospermia human testicles
676 reveals central role of Sertoli cells. *Nat. Commun.* **11**, 5683 (2020).
- 677 19. Sohni, A. *et al.* The Neonatal and Adult Human Testis Defined at the Single-Cell Level. *Cell*
678 *Rep.* **26**, 1501-1517.e4 (2019).
- 679 20. França, L. R., Hess, R. A., Dufour, J. M., Hofmann, M. C. & Griswold, M. D. The Sertoli
680 cell: one hundred fifty years of beauty and plasticity. *Andrology* **4**, 189–212 (2016).

- 681 21. Khan, M. *et al.* The evolutionarily conserved genes: *Tex37*, *Ccdc73*, *Prss55* and *Nxt2* are
682 dispensable for fertility in mice. *Sci. Rep.* **8**, 1–8 (2018).
- 683 22. Port, S. A. *et al.* Structural and Functional Characterization of CRM1-Nup214 Interactions
684 Reveals Multiple FG-Binding Sites Involved in Nuclear Export. *Cell Rep.* **13**, 690–702
685 (2015).
- 686 23. Nofrini, V., Di Giacomo, D. & Mecucci, C. Nucleoporin genes in human diseases. *Eur. J.*
687 *Hum. Genet.* **24**, 1388–1395 (2016).
- 688 24. Wang, P. J. & Pan, J. The role of spermatogonially expressed germ cell-specific genes in
689 mammalian meiosis. *Chromosom. Res.* **15**, 623–632 (2007).
- 690 25. Pan, J. *et al.* Inactivation of *Nxf2* causes defects in male meiosis and age-dependent
691 depletion of spermatogonia. *Dev. Biol.* **330**, 167–174 (2009).
- 692 26. Yang, J., Bogerd, H. P., Wang, P. J., Page, D. C. & Cullen, B. R. Two Closely Related
693 Human Nuclear Export Factors Utilize Entirely Distinct Export Pathways. *Mol. Cell* **8**, 397–
694 406 (2001).
- 695 27. Zhou, J. *et al.* *Nxf3* is expressed in Sertoli cells, but is dispensable for spermatogenesis.
696 *Mol. Reprod. Dev.* **78**, 241–249 (2011).
- 697 28. Takano, K., Miki, T., Katahira, J. & Yoneda, Y. NXF2 is involved in cytoplasmic mRNA
698 dynamics through interactions with motor proteins. *Nucleic Acids Res.* **35**, 2513–2521
699 (2007).
- 700 29. Batki, J. *et al.* The nascent RNA binding complex SFiNX licenses piRNA-guided
701 heterochromatin formation. *Nat. Struct. Mol. Biol.* **26**, 720–731 (2019).
- 702 30. Murano, K. *et al.* Nuclear RNA export factor variant initiates piRNA- guided co-
703 transcriptional silencing. *EMBO J.* **38**, e102870 (2019).
- 704 31. ElMaghraby, M. F. *et al.* A Heterochromatin-Specific RNA Export Pathway Facilitates
705 piRNA Production. *Cell* **178**, 964-979.e20 (2019).
- 706 32. Kneuss, E. *et al.* Specialization of the *Drosophila* nuclear export family protein *Nxf3* for
707 piRNA precursor export. *Genes Dev.* **33**, 1208–1220 (2019).
- 708 33. Mendel, M. & Pillai, R. S. *Nxf3*: a middleman with the right connections for unspliced piRNA
709 precursor export. *Genes Dev.* **33**, 1095–1097 (2019).
- 710 34. Pertschy, B. *et al.* Cytoplasmic Recycling of 60S Preribosomal Factors Depends on the
711 AAA Protein *Drg1*. *Mol. Cell. Biol.* **27**, 6581–6592 (2007).
- 712 35. Prattes, M., Lo, Y. H., Bergler, H. & Stanley, R. E. Shaping the Nascent Ribosome: AAA-
713 ATPases in Eukaryotic Ribosome Biogenesis. *Biomolecules* **9**, 715 (2019).
- 714 36. Kappel, L. *et al.* *Rlp24* activates the AAA-ATPase *Drg1* to initiate cytoplasmic pre-60S
715 maturation. *J. Cell Biol.* **199**, 771–782 (2012).
- 716 37. Li, H. *et al.* A male germ-cell-specific ribosome controls male fertility. *Nature* **612**, 725–731
717 (2022).
- 718 38. Ashburner, M. *et al.* Gene Ontology: tool for the unification of biology. *Nat. Genet.* **25**, 25–
719 29 (2000).
- 720 39. Aleksander, S. A. *et al.* The Gene Ontology knowledgebase in 2023. *Genetics* **224**, iyad031
721 (2023).
- 722 40. Thomas, P. D. *et al.* PANTHER: Making genome-scale phylogenetics accessible to all.
723 *Protein Sci.* **31**, 8–22 (2022).
- 724 41. Supek, F., Bošnjak, M., Škunca, N. & Šmuc, T. REVIGO summarizes and visualizes long

- 725 lists of gene ontology terms. *PLoS One* **6**, e21800 (2011).
- 726 42. Kuznetsova, I., Lugmayr, A., Siira, S. J., Rackham, O. & Filipovska, A. CirGO: An
727 alternative circular way of visualising gene ontology terms. *BMC Bioinformatics* **20**, 1–7
728 (2019).
- 729 43. Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased
730 coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic
731 Acids Res.* **47**, 607–613 (2018).
- 732 44. Wyrwoll, M. J. *et al.* Bi-allelic Mutations in M1AP Are a Frequent Cause of Meiotic Arrest
733 and Severely Impaired Spermatogenesis Leading to Male Infertility. *Am. J. Hum. Genet.*
734 **107**, 342–351 (2020).
- 735 45. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
736 *EMBnet.journal* **17**, 10 (2011).
- 737 46. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler
738 transform. *Bioinformatics* **25**, 1754–1760 (2009).
- 739 47. McKenna, A. *et al.* The genome analysis toolkit: A MapReduce framework for analyzing
740 next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).
- 741 48. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 1–14 (2016).
- 742 49. Van der Auwera, G. A. *et al.* From FastQ data to high confidence variant calls: the
743 GenomeAnalysis Toolkit best practices pipeline. *Curr. Protoc. Bioinformatics* **11**, 11.10.1
744 (2013).
- 745 50. Cleal, K. & Baird, D. M. Dysgu: efficient structural variant calling using short or long reads.
746 *Nucleic Acids Res.* **50**, e53–e53 (2022).
- 747 51. Robinson, J. T. *et al.* Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).
- 748 52. Kishore, S., Khanna, A. & Stamm, S. Rapid generation of splicing reporters with
749 pSpliceExpress. *Gene* **427**, 104–110 (2008).
- 750 53. Dohle, G. R. *et al.* EAU guidelines on male infertility. *Eur. Urol.* **48**, 703–711 (2005).
- 751 54. Minhas, S. *et al.* European Association of Urology Guidelines on Male Sexual and
752 Reproductive Health: 2021 Update on Male Infertility. *Eur. Urol.* **80**, 603–620 (2021).
- 753 55. Bergmann, M. & Kliesch, S. Testicular biopsy and histology. in *Andrology* (eds. Nieschlag,
754 E., Behre, H. M. & Nieschlag, S.) 161–172 (Springer-Verlag, 2009).
- 755 56. Nieschlag, E., Behre, H. M. & Nieschlag, S. *Andrology: Male reproductive health and
756 dysfunction. Andrology: Male Reproductive Health and Dysfunction* (2010).
- 757 57. Young, S. *et al.* Human fertilization in vivo and in vitro requires the CatSper channel to
758 initiate sperm hyperactivation. *J. Clin. Invest.* **134**, e173564 (2024).
- 759 58. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature* **596**,
760 583–589 (2021).
- 761 59. Varadi, M. *et al.* AlphaFold Protein Structure Database: massively expanding the structural
762 coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res.* **50**,
763 D439–D444 (2022).
- 764 60. Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580
765 (2013).
- 766 61. Perez-Riverol, Y. *et al.* The PRIDE database resources in 2022: a hub for mass
767 spectrometry-based proteomics evidences. *Nucleic Acids Res.* **50**, D543–D552 (2022).

768 ***Acknowledgment***

769 This study relied on data from probands who gave their permission for genomic analyses, and
770 the authors gratefully thank all participants and their family members. We further would like to
771 thank Sandra Laurentino, Leonie Herrmann, and Luisa Meier for critical reading of the manuscript.

772 This work was carried out within the frame of the Deutsche Forschungsgemeinschaft (DFG,
773 German Research Foundation) funded Clinical Research Unit 'Male Germ Cells' (CRU326,
774 project no. 329621271, grants to F.T. and N.N.). S.A.K. was supported by the 'Careers'
775 programme of the Medical Faculty Münster.

776 ***Author Contributions***

777 Study conceptualization: A.-K.D., B.S., F.T. Data curation: A.-K.D., B.S. Funding acquisition: F.T.
778 Investigation: A.-K.D., A.A., L.M., G.v.d.H., C.K., O.K., S.A.K., M.J.X., J.V., S.K., N.N., N.K., B.S.,
779 F.T. Visualization: A.-K.D. Writing of original draft: A.-K.D., B.S., F.T. All authors revised and
780 approved the final version of the manuscript.

781 ***Competing Interests***


The authors declare no competing interests.

NXT2 & nuclear RNA export


a Human adult testis interactome of NXT2

Protein	p-value	Enrichment
NXF1	1.96E-05	27.96
NXT2	1.83E-04	40.61
NXF3	2.50E-04	47.42
NXF2	6.59E-04	4.06
NUP214	7.06E-04	6.23
SPATA5	1.87E-03	12.90
SPATA5L1	3.34E-03	9.97
NUP93	2.47E-02	5.19

b STRING interaction analysis




c Biological Process




d Cellular Component




e Nuclear RNA export




f Expression of nuclear export proteins



g Co-IP of NXT2-NXF2



h Co-IP of NXT2-NXF3




783 **Figure 1: The testicular interactome of NXT2 indicates a testis-specific nucleocytoplasmic**
784 **RNA export pathway**


785 a. Results of mass spectrometry data of an NXT2 pulldown (N=4) from adult human testis
786 depicting proteins significantly ($p < 0.05$) and at least 4-fold enriched compared to the IgG control
787 (N=2) (two-sided t-test on protein abundance values). b. The STRING interaction analysis of
788 significantly enriched proteins identified three main clusters. The central cluster (red) includes
789 NXT2 and the nuclear export factors NXF1, NXF2, and NXF3. The blue cluster comprises two
790 nucleoporins (NUP93 and NUP214), and the green cluster includes the ribosome biogenesis
791 factors SPATA5 and SPATA5L1. c. Gene Ontology (GO) term analysis of significantly enriched
792 proteins highlights biological processes associated with NXT2 and its binding partners in a two-
793 tiered-hierarchy. Top GO terms were “mRNA transport” and “nuclear export”. Terms belonging to
794 the inner circular segment are listed. d. Name and relative proportion of GO terms describing the
795 cellular compartment associated with the NXT2 interactome. GO terms belonging to the inner ring
796 are indicated. e. Proposed models for testis-specific RNA export pathways with NXT2 as the key
797 player. At the top, the well-studied ubiquitous nuclear bulk mRNA export pathway involving NXT1
798 and NXF1 is depicted. In the middle and at the bottom, two possible testis-specific nuclear export
799 pathways are shown involving NXT2 and its testicular binding partners NXF2 and NXF3,
800 respectively. f. Box plots visualizing mRNA expression data of human nuclear export factor genes
801 derived from the Human Protein Atlas (nTPM = normalized transcripts per million). g. Western
802 blot analysis of Co-IP of NXT2-HA and NXF2-FLAG demonstrates that NXF2 binds to NXT2 *in*
803 *vitro* in lysates derived from NXT2-NXF2 co-transfection in HEK293T cells. h. Binding of NXT2 to
804 NXF3 was corroborated in NXT2 Co-IP of overexpressed proteins as shown in subsequent
805 Western blot analysis (bottom). Representative Western blots from at least three replicates (N =
806 3) are shown. Uncropped images of all Western blots depicted are provided in the Source data
807 file.

NXT2 & nuclear RNA export


a Deletion constructs of NXF2




b Co-IP of NXT2-NXF2^{NTF2LDdel}




c Co-IP of NXT2-NXF2^{RRMDdel}




d Deletion constructs of NXF3



e Co-IP of NXT2-NXF3^{NTF2LDdel}



f Co-IP of NXT2-NXF3^{RRMDdel}




808

809 **Figure 2: NXT2 binds to NXF2 and NXF3 by their NTF2-like domains.**


810 a. To scrutinize the protein domain mediating binding to NXT2, deletion constructs of NXF2-FLAG
811 lacking the NTF2-like domain (NXF2^{NTF2LDdel}) or the RNA recognition motif domain (NXF2^{RRMDdel})
812 were generated. b. Western blot analyses demonstrating specific expression of NXT2 and
813 NXF2^{NTF2LDdel} in protein lysates isolated from transfected HEK293T cells (top). In Co-IP analysis,
814 NXF2^{NTF2LDdel} is not able to bind to NXT2 (bottom). c. NXF2^{RRMDdel} still binds to NXT2 (cell lysates
815 derived from transfected HEK293T cells at the top, Co-IP at the bottom). d. Schematic depiction
816 of deletion constructs of NXF3-FLAG lacking the NTF2-like domain (NXF3^{NTF2LDdel}) or the RRM
817 domain (NXF2^{RRMDdel}). e. In Co-IP analysis, NXT2-NXF3 heterodimerization is dependent on the
818 NTF2-like domain in NXF3. f. In Co-IP analysis of NXT2 and NXF2^{RRMDdel}, binding of both proteins
819 is still possible, indicating that the RRM domain is dispensable for dimerization. Representative
820 Western blots of at least three replicates are shown. Uncropped images of all Western blots
821 depicted are provided in the Source data file.

NXT2 & nuclear RNA export


a Localization of *NXT2* variants




b Testicular phenotypes



d *NXT2* expression



c Germ cell detection via MAGEA4 staining




822

823

824 **Figure 3: Loss-of-function variants in *NXT2* are associated with male infertility due to**
825 **disturbed germ cell development.**

826 a. Schematic depiction of the *NXT2* exon-intron-structure and the *NXT2* primary protein structure
827 with the position of NTF2-like domain highlighted. Red dots indicate the localization of the
828 identified *NXT2* variants at the gene and protein level. The missense variant p.(Ala90Ser)
829 identified in M2004 and the LoF variant p.(Asp119*) identified in M3065 are both located within
830 the NTF2-like domain. The deletion identified in RU00584 encompasses the entire *NXT2* gene.
831 b. Overview of the testicular phenotype of all three men with variants in *NXT2* (PAS staining of
832 testicular sections) compared to a control with full spermatogenesis. All subjects consistently had
833 a Sertoli cell-only phenotype, i.e. a complete lack of germ cells, in the vast majority of seminiferous
834 tubules. Sertoli cells are exemplary marked by arrows. c. Immunohistochemical staining for germ
835 cell marker protein MAGEA4 reveals only sparse seminiferous tubules with few spermatogonia
836 and spermatocytes only in M3065. No haploid germ cells were identified. d. In fetal male germ
837 cells (left), *NXT2* is highly expressed in germ cells according to scRNA-seq data. In the adult
838 testis (right), *NXT2* is mainly expressed in spermatogonia but also in Sertoli cells and in all germ
839 cell stages up to spermatids in two different data sets (EC: endothelial cells; FLC: fetal Leydig
840 cells; LC: Leydig cells; SC: Sertoli cells; GC: germ cells; SPG: spermatogonia; SPC:
841 spermatocytes; RS: round spermatids).

NXT2 & nuclear RNA export




842

843 **Figure 4: The *NXT2* variant c.354dup p.(Asp119*) co-segregates with azoospermia and**
844 **leads to *NXT2* deficiency.**


845 a. Index subject M3065 carries a duplication of a thymine at position 354 of the *NXT2* open
846 reading frame resulting in the direct inclusion of a premature stop codon. The variant is inherited
847 from the female parent (P1, heterozygous carrier) and is also present in two male siblings (S1,
848 S3) with azoospermia. The variant is absent in the only fertile male sibling (S2). b. AlphaFold2
849 prediction of the short isoform (NM_001242617.2) of wildtype *NXT2* (left). Inclusion of a
850 premature stop codon results in the loss of 78 amino acids at the protein C-terminus (transparent,
851 right). c. In Western blot analysis of protein lysates derived from overexpression of mutant *NXT2*-
852 HA, no protein was detectable. d. Sertoli cells show positive SOX9 staining in control's and
853 M3065's testicular tissue. In contrast, *NXT2*-specific staining, which is mainly visible in Sertoli
854 cells and spermatogonia in the control tissue (as exemplary indicated by arrows; top), is absent
855 in the subject (bottom).

NXT2 & nuclear RNA export

a CNV Plot of RU00285



b SOX9 and *NXT2* expression in Ctrl. and M3065




856

857 **Figure 5: Deletion of the entire *NXT2* gene in RU00584 occurred *de novo* and results in**
858 **the absence of *NXT2* *in vivo*.**

859 a. Robot (CNV) plot of genome sequencing data illustrating the presence of a 42 kb deletion in
860 RU00584 encompassing the entire *NXT2* gene and surrounding genomic regions. The deletion
861 is absent in both parents, demonstrating *de novo* occurrence in the subject. b. *In vivo*,
862 immunohistochemical staining for the Sertoli cell marker protein SOX9 confirms the presence of
863 Sertoli cells in the control (top) and in RU00584 (bottom). In an immunohistochemical staining for
864 *NXT2*, in contrast to the control, no *NXT2*-specific staining was observed in Sertoli cells in
865 RU00584.

NXT2 & nuclear RNA export



867 **Figure 6: A LoF variant in *NXF3* is associated with quantitatively and qualitatively**
868 **severely impaired sperm production**

869 a. Schematic depiction of the exon-intron-structure of *NXF3* with the variant c.826G>T in exon
870 nine indicated by a red dot. b. At the protein level, the variant leads to the inclusion of a premature
871 stop codon p.(Gly276*), resulting in a truncated protein lacking the NTF2-like domain if the mutant
872 transcript is not degraded by NMD. c. Pedigree of M2799 demonstrating hemizygous presence
873 of c.826G>T in the index case. The variant is inherited from the heterozygous female parent (P)
874 and two fertile male relatives (R1, R2) are negative for the variant. d. *In vitro*, the variant leads to
875 the expression of a C-terminally truncated *NXF3*-FLAG protein (expected size: ~32 kDa). e.
876 Western blot analysis of lysates derived from overexpressed mutant *NXF3* in HEK293T cells (left).
877 Co-IP of HA-tagged *NXT2* and mutant FLAG-tagged *NXF3* demonstrates abolished binding of
878 the truncated *NXF3* protein to *NXT2* (right). f. Immunofluorescence staining for *NXF3* and sperm
879 tail and midpiece marker in sperm from healthy donors and M2799. In control sperm (top left),
880 *NXF3* staining localized to the neck, very closely attached to the sperm head. In the subject's
881 sperm (bottom left), *NXF3* staining was absent, indicating absence of the protein. Sperm were
882 characterized by staining for specific marker proteins. The head (DAPI) is stained blue, the
883 flagellum (α/β -tubulin) is stained green and the midpiece (Mitotracker, exemplary indicated by a
884 white arrow) is stained red (right). M2799 sperm did not show specific staining for the midpiece
885 marker Mitotracker (right bottom).